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Abstract Since the development of federal standards for drug approval, the practice
of medicine has historically involved the compounding of medications based
on a physician’s determination that a US FDA-approved product either did
not exist, or could not be used for medical reasons. Today, prescriptions for
non-FDA-approved compounded drugs may be driven by fanciful and large-
ly unregulated pharmacy advertisements to physicians and patients and/or
payer reimbursement policies, thus placing prescribers in the backseat for
clinical decision making. This article outlines essential differences between
FDA-approved drugs and compounded drugs and reasserts the primary
medical role of physicians for determining what medical circumstances may
necessitate treatment with non-FDA-approved products. In addition, liabi-
lity concerns when prescribing non-FDA-approved drugs are discussed.
While representing a US perspective, underlying principles apply globally in
the setting of magistral and extemporaneous formulations produced outside
national regulatory frameworks.
1. Introduction
Since the development of federal standards for
drug approval, the professions of pharmacy and
medicine have their earliest roots in drug compound-
ing. In centuries past, doctors and pharmacists
created individual therapies according to patient
needs and the medical and scientific principles of
the time. With the development of commercial
manufacturing, pharmacies gradually transitioned
into dispensaries of standardized drug products
manufactured by the pharmaceutical industry and
subject to federal oversight and regulation. While
US FDA-approved drug products currently meet
the therapeutic needs of most patients, there are
certain circumstances in which compounded drugs
play an important role in medical care. While the
scope of the paper is focused primarily on the US
experience, principles apply equally to magistral or
extemporaneous formulations that are produced
outside national regulatory frameworks around the
globe and for which differentiation and discrimina-
tion of this unique benefit-risk setting is critical for
therapeutic decision making.
2. Drugs Approved and Regulated by the
US FDA
FDA-approved drugs include both branded
and generic products. Branded drugs are rigor-
ously reviewed by the FDA for quality, safety
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and efficacy under a New Drug Application
(NDA). Approval of an NDA requires substantial
evidence of effectiveness, defined under the Federal
Food, Drug and Cosmetic Act (FFDCA) as ‘‘evi-
dence consisting of adequate and well-controlled
investigations by experts qualified by scientific
training and experience to evaluate the effective-
ness of the drug involved, on the basis of which it
could fairly and responsibly be concluded by such
experts that the drug will have the effect it purports
or is represented to have under the conditions of
use prescribed, recommended, or suggested in the
proposed labeling.’’[1] In general, drugs approved
under an NDA have demonstrated a positive
benefit-risk balance for their intended use on a
population level. Generic drugs are reviewed and
approved for quality and bioequivalency to an
FDA-approved reference drug under an Abbre-
viated NDA (ANDA). Both brand and generic
drugs are required by law to be produced under
federal Good Manufacturing Practice (GMP) reg-
ulations, a detailed and complex set of working
standards established through federal regulation to
ensure products meet specific requirements for
identity, quality, potency and purity. Pharmaceu-
tical manufacturers are periodically inspected by
the FDA for adherence toGMP regulations and to
ensure that GMP-driven quality standards estab-
lished for drugs manufactured for scientific evalu-
ation in clinical trial populations[2] are met or
exceeded for drugs manufactured for commercial
distribution.[3]
3. Compounded Drugs and Traditional
Pharmacy Compounding
In response to a prescription, pharmacists may
combine, mix or alter ingredients to create unique
medications in accordance with traditional com-
pounding. A compounded drug may be necessary,
for example, to treat a patient with a documented
allergy to a drug ingredient, or to provide a liquid
dosage form for a child who is unable to swallow
tablets. A primary tenet of traditional compounding
is that an FDA-approved product should be used
wherever possible to meet a patient’s individual
medical needs, because, despite best compounding
practices,[4] extemporaneous formulations generally
lack studies to document stability, bioavailability,
pharmacokinetics, pharmacodynamics, efficacy and
safety.[5,6] This tenet restricts the use of compounded
drugs to where they are medically necessary and
protects the public from intentional circumvention
of the FDA approval and regulatory process that
consumers rely on for safe and effective therapies
(table I).
State Boards of Pharmacy oversee pharmacy
practices, including drug compounding. When
the FDA learns of compounding practices that
raise public health concerns, the agency may refer
the matter to State Boards of Pharmacy for in-
vestigation.[7] Using a risk-based approach,[8] the
FDA may take enforcement action against
pharmacies for circumstances described in FDA
Guidance that are not consistent with traditional
compounding, including but not limited to the
following:[9]
1. Compounding drugs prior to receipt of a valid
prescription.
2. Compounding drugs removed from the mar-
ket for safety reasons.
3. Compounding drugs that are essentially
copies of commercially available products.
Table I. Key differences between US FDA-approved and com-
pounded drugs
FDA-approved
drug
Compounded
drug
Made ‘extemporaneously’
after receipt of prescription
No Yes
Reviewed by FDA for
quality, safety and efficacy
prior to marketing/
prescribing
Yes No
Manufactured under
federal GMP regulations
Yes No
Labelling for safe
prescribing and use
required and regulated
Yes No
Sterile products adhere to
federal GMP sterility
requirements
Yes No
Benefit-risk assessment Conducted by
FDA at
population level
Conducted by
prescriber at
patient level
GMP =Good Manufacturing Practice.
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Compounded drugs may be made starting
with FDA-approved brand or generic drugs, for
example, a tablet or capsule may be converted to
a liquid form for administration to a child. Ben-
efits of compounding from approved dosage
forms include basic confirmation of the identity
of the active ingredient and its initial dose. Po-
tential disadvantages include formulation com-
plications from inactive ingredients that may not
be suitable for the compounded formulation.
Compounded drugs may also be made with ac-
tive pharmaceutical ingredients (API) and other in-
active components. Benefits of compounding from
APIs include the avoidance of binders, and the
possibility of accessing drug substances that are
not available in suitable commercial forms for
the intended use of the compounded product. For
example, an oral tablet may contain inactive in-
gredients that should not be administered by the
intravenous route. If such a drug is necessary, it may
be preferable to start with an appropriate API, if
available. Disadvantages of compounding with
APIs include, first and foremost, uncertainty re-
garding the substance’s identity, purity and po-
tency. In addition, due to the complex nature of
our global supply chain, an API’s origin and dis-
position throughout the supply chain, including
shipping, storage conditions and repackaging,
may be difficult for pharmacies and physicians to
verify.[10]
By necessity, compounded drugs are made
under standards that are less stringent than those
applied to FDA-approved products. It would be
impossible, for example, to apply for FDAapproval
for drugs compounded on an individual, extempo-
raneous basis. Further, traditional pharmacies
would find it difficult to comply with the complex-
ities of federal GMP requirements under the
FFDCA. However, some facilities operating under
less rigorous pharmacy standards actually manu-
facture large quantities of standardized dosage
forms without adherence to federal manufacturing
standards. Such business practices, deemed by for-
mer FDA Commissioner David Kessler, MD, as
‘‘manufacturing under the guise of pharmacy com-
pounding,’’ undermine the FFDCA and place po-
pulations at risk for substandard drug exposures.[11]
Because of the inherent differences between federal
manufacturing and approval standards and profes-
sional (pharmacy) standards with respect to pur-
pose, scope and enforceability, physicians should be
cautious in their judgements regarding what cir-
cumstances would justify setting aside a federal
standard for a professional one.
3.1 Risks Associated with Compounded
Medications
Pharmacy-compounded drugs have been associ-
ated with quality defects, infectious disease out-
breaks and other adverse events which, in some
cases, have involved patient deaths.[7,12-17] Because
federal surveillance requirements do not exist for
compounded drugs, the extent of quality and safety
problems is unknown.[18]
3.1.1 Substandard Products
While surveillance is limited, quality defects
have been reported in conjunction with product
recalls, as outcomes of formal, limited investiga-
tions by the FDA and Missouri State Board of
Pharmacy, and as independent studies.[17,19-24]
In 2004, roughly 1.4million doses of com-
pounded respiratory solution contaminated with
Burkholderia cepacia were distributed to patients
nationally. TheMissouri State Board of Pharmacy
found the pharmacy did not adequately recall po-
tentially affected product and failed to advise
patients and prescribers of the contamination risk.
The Board issued a temporary restraining order,
noting in their petition that the pharmacy ‘‘engaged
in practices that pose a threat of immediate and
irreparable injury, loss or damage to patients
and presents a probability of serious danger to the
health, safety or welfare of the residents of the
state.’’[25]
In 2006, the FDA conducted a limited survey of
compounded drugs. Of 36 samples tested by the
FDA, 12 failed at least one quality test, for a fail-
ure rate of 33%. Further, oral hormone dosage
forms containing multiple active ingredients
showed poor content uniformity, with random
variation in all three active ingredients from cap-
sule to capsule.[19]
TheMissouri State Board of Pharmacy initiated
routine sampling and testing of compounded drugs
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after pharmacist Robert Courtney was found to
have supplied thousands of cancer patients with
substandard chemotherapy that provided only a
fraction of prescribed doses.[26] For the years
2006–2009, the Board of Pharmacy testing re-
vealed that failure rates averaged roughly 20%
(range 11.6–25.2), with individual findings ranging
from 0% to 450% of labelled potency.[23] While the
Courtney case involved drug reconstitution and
admixing of FDA-approved products, it is critical
to this discussion because it illustrates an im-
portant limitation of clinical medicine: the dilution
scheme went on for years and affected thousands
of patients, yet medical observation alone failed to
detect lack of effect, including both therapeutic
response and expected chemotherapy-related toxi-
city. In the absence of federal oversight, clinical
observation or experience alone may be a poor
surrogate for ensuring the quality, safety and ef-
fectiveness of compounded drugs.
In a 2004 published analysis sponsored by STD
Pharmaceuticals,[27] all samples purchased from
three compounding pharmacies failed content test-
ing for a 3% sodium tetradecyl sulfate solution for
injection (range 2.59–3.39). Significant concentra-
tions of the contaminant carbitol were found to be
present in samples from all three sources (0.33–
4.18), suggesting possible use of a non-pharma-
ceutical grade chemical. In response to the assay
results, dermatologistMitchel Goldman concluded
that ‘‘Physicians need to be aware that the stated
concentration may not be correct and that along
with sodium tetradecyl sulfate, potentially harmful
contaminants may be present in the solution.’’
Mahaguna et al.[28] reported an analysis of
compounded progesterone suppositories from
ten randomly selected pharmacies. Nine of the
ten pharmacies provided suppositories that fell
outside potency limits set for approved products
and one pharmacy provided suppositories testing
positive for Comamonas acidovorans bacteria.
In a similar analysis sponsored by Ther-Rx
Corporation, eight of nine samples of hydroxypro-
gesterone caproate API accessible to pharmacies for
compounding did not meet impurity standards ap-
plicable for manufacturing the approved product
and 16 of 30 samples of hydroxyprogesterone
injection samples purchased from compounding
pharmacies exceeded impurity limits for the ap-
proved product. One additional sample of API
labelled as hydroxyprogesterone caproate did not
contain any active ingredient and was subsequently
found to contain only glucose.[17]
3.1.2 Morbidity and Mortality Associated with
Compounded Drugs
Because pharmacies are not required to conduct
surveillance or report adverse events associated
with drugs they make, the extent of compounded
drug-associatedmorbidity andmortality cannot be
assessed. Sentinel events involving compounded
drugs have become known through sporadic re-
porting by the FDA and the Centers for Disease
Control and Prevention (CDC), through case re-
ports published in the literature, and through
media reporting. These events are considered the
‘tip of the iceberg’ by public health experts, because
there is little if any transparency as to the extent of
exposure to non-FDA-approved, pharmacy com-
pounded drugs and the rate of occurrence of ad-
verse events.[12]
Examples of preventable adverse events in-
clude but are not limited to the following:
 An outbreak ofPseudomonas fluorescens blood-
stream infections associated with compounded
catheter flush solutions occurred in four states
during 2004–5. The CDC noted that sterility
testing of finished products, mandated for
FDA-approved products, was reportedly not
performed in this case and concluded ‘‘Compa-
nies that manufacture products intended for
injection should follow FDA regulations for
ensuring the sterility of these products.’’[14]
 Whelan et al.[15] reported a probable treatment
failure in a poorly controlled asthma patient with
severe disease. An analysis found that the
patient’s inhalation therapy contained an aver-
age of 36.8% of active ingredient for the five vials
assayed by high-performance liquid chromato-
graphy (HPLC).Authors note that these findings
highlight major concerns with using com-
pounded products that are not FDA approved.
 A cluster of streptococcal endophthalmitis infec-
tions was reported to the FDA by the Florida
Department of Health following intravitreal
injection of repackaged bevacizumab (Avastin).
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At least 12 patients developed eye infections,
with some losing all remaining vision.[16]
3.2 Controversial Roles of Compounding
While there is a place for traditional pharmacy
compounding to fulfil medical needs of individuals
that cannot be met with commercially available
products, these more controversial aspects threaten
to circumvent important public health regulations
at the population level. Some controversial uses of
pharmacy compounding include the introduction
of drug moieties that have been denied or removed
from the US market, the mass marketing of spe-
cific, non-FDA-approved formulations, and the
compounding of drugs for economic reasons.
An interesting example involves the drug 4-
aminopyridine. Although physicians had been
prescribing unapproved versions of the drug for up
to 20 years, it was not until the drug was studied
systematically that rare seizures were discovered as
a potential side effect. In this case, the medical
profession pushed for an approved version to be
marketed, rationalizing that if a seizure occurred in
the context of a patient taking an FDA-approved
alternative, ‘‘at least you know it wasn’t because of
a local compounding pharmacy error.’’[29]
Another significant example has been the rapid
growth of the so-called ‘bioidentical postmeno-
pausal hormone therapy’ market. Following the
abrupt termination of the estrogen-progestogen
arm of the National Institutes of Health (NIH)
Women’s Health Initiative Study in July 2002, an
alternative market developed promoted by com-
pounding pharmacies and health providers, often
with cross-interests. Not subject to the reporting
requirements imposed on the pharmaceutical indus-
try, the bioidentical compounding industry has
made major claims of absence of risk and main-
tenance of benefits of hormone therapy, despite the
fact that the basic molecules being compounded
are, in most instances, the same as those of FDA-
approved products.[30] The FDA has found dis-
crepancies and has issuedWarning Letters to many
compounders, but this alternate industry continues
to flourish with major marketing efforts.[31]
An example of pharmacy compounding purely
for cost-saving purposes involves the recently
approved drug,Makena (17a-hydroxyprogester-
one caproate injection). Citing a ‘‘unique circum-
stance,’’ the FDA announced the agency would
continue to exercise enforcement discretion and
not enforce the FFDCA for compounded versions
of the newly approved drug if pharmacies
produced the alternatives in accordance with
‘‘traditional compounding.’’[32] The announcement
created considerable confusion in the prescribing
and reimbursement communities, to the extent that
some stakeholders interpreted the FDA enforce-
ment discretion language to mean that compoun-
ded versions of 17a-hydroxyprogesterone caproate
had been approved by the FDA for safety and
efficacy. On 29 June 2012, the FDA clarified its re-
gulatory language for prescribers, payers and pa-
tients, stating that ‘‘when an FDA-approved drug is
commercially available, the FDA recommends that
practitioners prescribe the FDA-approved drug ra-
ther than a compounded drug unless the prescribing
practitioner has determined that a compounded
product is necessary for the particular patient and
would provide a significant (medical) difference for
the patient as compared to theFDA-approved com-
mercially available drug product.’’[8] This statement
holds at its very core the fundamental public health
values of the FFDCA. FDA-approved products
produced under federal GMPs represent an essen-
tial standard of pharmaceutical care relied on byUS
citizens, and deviations from this standard of care
should be made only under rare circumstances of
medical necessity.
3.3 Medico-Legal Risks for Physicians
Few prescribing physicians escape concerns
during their day-to-day practice of the ‘lawyer
looking over their shoulder’. The prescribing of
compounded drugs involves the triad of patient,
physician prescriber and compounding pharmacy.
When prescribing an FDA-approved drug ac-
cording to labelled indications, in the event of an
adverse outcome the physician is protected by the
FDA approval process and background support
of a major pharmaceutical company, thus unlikely
to face personal liability. Unlike FDA-approved
products, there is no requirement by compounders
to provide a patient package insert listing risks and
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benefits, and the marketing invariably has mini-
mized possibility of risks. Consequently, prescribers
of compounded products may be personally ex-
posed should there be an adverse event as a result of
administering a product that neither the prescriber
nor the compounder can prove to have been pure
and free of active contaminants, of correct dose,
sterile, etc.[33] Indeed, the FDA has attempted to
avoid such risks by its policy against compounding
products when an FDA-approved drug exists.
Physicians should also be aware that the liability
based on inappropriate use of a non-FDA-app-
roved drug can be significant, and possible negative
consequences can include the invalidation of their
malpractice insurance, personal liability and poss-
ible criminal prosecution. This is a situation beyond
buyer beware that really is ‘prescriber beware’.
Prescribing physicians can lessen malpractice
exposure. The simple and direct approachwould be
to only prescribe FDA-approved products, with
the sole exception for those patients who require an
alternative form that is not available commer-
cially.[34] If prescribers are motivated to prescribe
compounded products, and reduced cost is not
legally viable as a sole reason, then that prescriber
needs to take some active steps to ensure the patient
is receiving exactly what was prescribed. These in-
clude ascertaining that an FDA-approved equiva-
lent is not available, acquiring information from the
compounding pharmacist as to whether their facil-
ity is FDA registered, where the raw product was
obtained and whether it is pharmaceutical grade for
humans, how the batch is stored, whether it has
been tested for purity, how and when the product
was compounded including sterility, and whether
the equipment is free of contaminants of other
drugs. It is strongly recommended that documen-
tation about responses to these queries be included
in the patient record, confirming that the prescriber
has taken every step available to them to ensure that
the patient is receiving the medication prescribed.
4. Important Considerations for
Prescribers
Compounding practices have emerged through-
out the US and other countries as novel pharmacy
business models that offer expanded compounding
services with direct marketing of unique formula-
tions to patients and prescribers. Because the idea
of using a compounded product in today’s mar-
ketplace may not arise solely from a physician’s
identification of amedication problem that requires
an alternative to an FDA-approved product,
physicians should have a basic understanding of
the benefits and risks of compounded drugs to
support therapeutic decision making and to help
educate patients about their treatment options.
In this regard, prescribers are reminded of the
following:
 That compounded drugs lack an FDA finding
of safety, efficacy and manufacturing quality.
 That compounded drugs are not interchange-
able with FDA-approved brand or generic
medications.
 That, if an FDA-approved drug is available,
the FDA-approved product should be pre-
scribed and used.
 That liability concerns may arise due to
prescribers’ role as a learned intermediary if
patient harm arises in association with com-
pounded drugs.
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